The World Health Organization's (WHO) Technical Advisory Group recommends updating future COVID-19 vaccines to a monovalent LP.8.1 formulation. This guidance helps manufacturers enhance immune responses against currently circulating SARS-CoV-2 variants.
Several manufacturers using mRNA platforms, including Moderna, have already updated their vaccines to the LP.8.1 formulation.
Data indicates monovalent JN.1 and KP.2 mRNA vaccines provide additional protection against symptomatic and severe COVID-19. The recommendation aims to maintain vaccine effectiveness as the virus continues to evolve globally.